Real-World Evidence of SUL-DUR on Special Populations with CRAB Infection RFP Grant
Funding Amount
Up to US $27,000
Deadline
Deadline not published
Grant Type
Foundation
Overview
Note:
Requesting organization must be legally able to receive award funding directly from Pfizer Investment Co., Ltd.. We strongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer Investment Co., Ltd. may be subject to rescission.
About Pfizer Grants
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Real-World Evidence of SUL-DUR on Special Populations with CRAB Infection
This competitive program aims to evaluate the real-world evidence on effectiveness and safety of Sulbactam-Durlobactam (SUL-DUR), as well as the influence of SUL-DUR treatment timing on clinical outcomes in special adult populations. The study will focus on patients with suspected or confirmed carbapenem-resistant Acinetobacter baumannii (CRAB) infection in China. Special populations include critically ill patients; recipients with solid organ transplant (SOT); and patients with hematological diseases.
Project Types and Area of Interest
Potential applicants are requested to submit research proposals to study realworld evidence on effectiveness, safety of SUL-DUR, and influence of SULDUR treatment timing on clinical outcomes for CRAB infections in special adult populations.
Critically ill patientsSOT patientsPatients with hematological diseases
What The Pfizer Foundation Inc actually gave
Source: IRS Form 990-PF, 2024
- Grants in 2024
- 9,306
- Total given
- $23.24M
Focus Areas & Funding Uses
Fields of Work
- Science research
- Healthcare
Categories
Browse similar grants by category
Related Grants
Open grants from this funder and similar programs
Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple Myeloma Grant
The Pfizer Foundation Inc
Amount
US $50,000 - US $200,000
Deadline
Deadline not published
Pfizer Clostridioides difficile (C. difficile) Research Collaboration Grant
The Pfizer Foundation Inc
Amount
Up to US $500,000
Deadline
Deadline not published
Bronchoscopy Research Grant
Intuitive Foundation
Amount
Up to US $75,000
Deadline
January 4, 2027
Listed date — confirm with the funder
Personal Health Informatics for Delivering Actionable Insights to Individuals (R01 Clinical Trial Optional)
National Institutes of Health
Amount
Up to $250,000
Deadline
January 7, 2027
Genomic Data Generation Center for the Gabriella Miller Kids First Pediatric Research Program (U24 Clinical Trial Not Allowed)
National Institutes of Health
Amount
$6,600,000 total
Deadline
January 8, 2027
Medical Scientist Training Program (MSTP) (T32)
National Institutes of Health
Amount
Varies
Deadline
January 25, 2027
Ready to apply for Real-World Evidence of SUL-DUR on Special Populations with CRAB Infection RFP Grant?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found Real-World Evidence of SUL-DUR on Special Populations with CRAB Infection RFP Grant. Now let's win it.